A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)

NCT06205953 · tracked via the Priya Life Science Italy tracker

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Phase

Observational

Started

2024-01-01

Last updated

2026-04-16

Condition(s) studied

AL Amyloidosis

Study summary

A prospective patients' registry collecting all new cases of AL amyloidosis evaluated at referral Centers from across Europe and a sample sharing network will be created to study mechanisms of the disease through the use of advanced molecular technologies and big data analysis tools.

Eligibility

Sex

ALL

Min age

18 Years

Max age

99 Years

Healthy volunteers

Inclusion Criteria: * diagnosis of systemic AL amyloidosis; * treatment-naïve; * age ≥18 years; * ability to understand and willingness to sign an informed consent; * planned follow-up at participating center. Exclusion Criteria: * non-AL amyloidosis; * previous treatment for AL amyloidosis.

Primary outcome measure(s)

Mortality at 24 months by stage — 24 months from diagnosis
Mortality at 24 months by stage will be evaluated

Trial sites (6)

Facility	City	Region	Status
Medical Department, Amyloidosis Center, University Hospital, Im Neuenheimer Feld 672	Heidelberg	Germany	Recruiting
Fondazione IRCCS Policlinico San Matteo, Pavia, Viale Golgi 19, 27100	Pavia	Italy	Recruiting
UMC Utrecht, dept Hematology, Amyloid Expertise Center, Utrecht, Heidelberglaan	Utrecht	Netherlands	Recruiting
Instituto de Investigación Sanitaria de Navarra (IdiSNA) C. de Irunlarrea, 3, 31008 Pamplona, Navarra	Pamplona	Spain	Recruiting
University of Applied Sciences and Arts Northwestern Switzerland, Institute of Medical Engineering and Medical Informatics	Muttenz	Switzerland	Active Not Recruiting
Universidad de la Republica Hospital de Clinicas "Dr Manuel Quintela"	Montevideo	Uruguay	Recruiting

More Fondazione IRCCS Policlinico San Matteo di Pavia trials in Italy

Italian Validation of a Pressure Injury Risk Assessment Scale (Braden QDS) in the Neonatal Intensive Care Unit Recruiting

ACU_Knee: Role of Acupuncture in Knee Prosthetic Surgery Recruiting

In Vitro Study on Donor Corneas Preservation in IRESTORE Storage Medium. A Post Marketing Interventional Study on Device Active, not recruiting

Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combination for Acute Myeloid Leukemia Patients in Remission. Recruiting

Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS Recruiting

Other trials for the same condition

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis Active, not recruiting

One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS Recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) Active, not recruiting

Promoting Diagnosis and Management of AL in Italy (ProDigALIty) Recruiting

Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06205953 on ClinicalTrials.gov ↗ ← All trials in Italy